The Indian way in pharma regulation

The Supreme Court verdict denying a patent to Novartis for an updated version of the firm's anti-cancer drug Glivec may have a far greater impact in India and outside than was earlier realised, when India became TRIPS (Trade-Related Aspects of Intellectual Property Rights) compliant by amending its patent Act in 2005. The judgment intellectually validates the Indian law and brings out its implications, offering leads to the global quest for a way to aid the discovery of new and better drugs while making them affordable.

Read Full Story>>